GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eton Pharmaceuticals Inc (NAS:ETON) » Definitions » Sloan Ratio %

Eton Pharmaceuticals (Eton Pharmaceuticals) Sloan Ratio % : 0.00% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eton Pharmaceuticals Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Eton Pharmaceuticals's Sloan Ratio for the quarter that ended in Mar. 2024 was 0.00%.

As of Mar. 2024, Eton Pharmaceuticals has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Eton Pharmaceuticals Sloan Ratio % Historical Data

The historical data trend for Eton Pharmaceuticals's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eton Pharmaceuticals Sloan Ratio % Chart

Eton Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial 9.09 -21.18 19.39 -44.16 -21.98

Eton Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eton Pharmaceuticals's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eton Pharmaceuticals's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Eton Pharmaceuticals's Sloan Ratio % falls into.



Eton Pharmaceuticals Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Eton Pharmaceuticals's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-0.936-6.815
--0.775)/31.74
=-21.98%

Eton Pharmaceuticals's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(0.913-5.89
--1.882)/30.794
=-10.05%

Eton Pharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was 4.559 (Jun. 2023 ) + -0.579 (Sep. 2023 ) + -2.256 (Dec. 2023 ) + -0.811 (Mar. 2024 ) = $0.91 Mil.
Eton Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 7.103 (Jun. 2023 ) + 0.873 (Sep. 2023 ) + 0.387 (Dec. 2023 ) + -2.473 (Mar. 2024 ) = $5.89 Mil.
Eton Pharmaceuticals's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) + -1.882 (Mar. 2024 ) = $-1.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eton Pharmaceuticals  (NAS:ETON) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Eton Pharmaceuticals has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Eton Pharmaceuticals Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Eton Pharmaceuticals's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eton Pharmaceuticals (Eton Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eleven product candidates in various stages of development.
Executives
David Krempa officer: Chief Business Officer 29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Sean Brynjelsen director, officer: President & CEO C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010
James R. Gruber officer: Chief Financial Officer 618 AMES STREET, LIBERTYVILLE IL 60048
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
William Wilson Troutman officer: CFO, Treasurer & Secretary 21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Imprimis Pharmaceuticals, Inc. 10 percent owner 102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215
Jennifer Mckie Adams director 5410 TENNESSEE AVE, NASHVILLE TN 37209
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Mark L Baum director C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121

Eton Pharmaceuticals (Eton Pharmaceuticals) Headlines